More on Medicines Company Q4: FDA accepts NDA for antibiotic

|About: The Medicines Company (MDCO)|By:, SA News Editor

The FDA has accepted Medicines Company's (MDCO +1.7%) filing of a new drug application (NDA) for the firm's Oritavancin intravenous antibiotic, with priority review, for the treatment of certain types of skin infections. (PR)

Q4 adjusted net income decreased 38% to $17.7M.

Total net income dropped to $1.2M from $20.7M.

Amortization of acquired intangible assets 10.1M.

During Q4, Medicines Company completed the acquisition of Rempex Pharmaceuticals and a co-promotion partnership with Boston Scientific. (PR)

Previous